openPR Logo
Press release

Global Peptide Vaccine Market & Clinical Pipeline Outlook 2020 Report

05-07-2018 07:45 AM CET | Health & Medicine

Press release from: Kuick Resarch

Global Peptide Vaccine Market & Clinical Pipeline Outlook 2020

“Global Peptide Vaccine Market & Clinical Pipeline Outlook 2020” Report Highlights:

* Introduction & Classification of Peptide Vaccines
* Designing & Production of Peptide Vaccine
* Mechanism of Peptide Vaccine
* Cancer Immunotherapy with Peptide Vaccine
* Global Peptide Vaccine Clinical Pipeline by Company, Indication & Phase
* Global Peptide Vaccine Clinical Pipeline: 97 Vaccine
* Majority vaccines in Preclinical Phase: 28 Vaccines
* Global Peptide Vaccine Market Future Prospects

Download Report Sample Weblink:

https://www.kuickresearch.com/report-Global-Peptide-Vaccine-Market-&-Clinical-Pipeline-Outlook-2020.php

For Report Sample Contact: neeraj@kuickresearch.com

Table of Contents

1. Peptide Vaccine: A Prologue to Sub-Unit Vaccines

1.1 Introduction

1.2 Glimpse of Antiquity



2. Need of Peptide Vaccines

2.1 Why Peptides – More Desirable

2.2 Peptide Vaccines V/S Traditional Vaccines



3. Classification of Peptide Vaccines

3.1 On the Basis of Sources Obtained

3.2 On the Basis of Length

3.3 On the Basis of Epitopes



4. Designing & Production of Peptide Vaccine

4.1 Synthetic Peptide Vaccine

4.2 Selection of Peptide Antigen

4.3 Construction of Peptide Antigen

4.4 Chemical Synthesis of Peptide Vaccine

4.4.1 Solution Phase Synthesis (SPS)

4.4.2 Solid Phase Peptide Synthesis (SPPS)



5. Mechanism of Peptide Vaccine

5.1 Induction of Immune Response

5.1.1 Factors Affecting T-Cell Stimulation

5.1.2 Factors Affecting B-cell Stimulation

5.1.3 Factors Affecting T-helper Cells

5.2 Delivery System for Peptide Vaccines

5.2.1 Immunostimulatory Adjuvants

5.2.2 Vaccine Delivery System

5.3 Multiple Antigen Peptide System (MAP)

5.3.1 Use of MAP for Foot-and-Mouth Disease



6. Cancer Immunotherapy with Peptide Vaccine

6.1 Peptides as Tumor Antigens

6.2 Immunotherapy with Peptide Vaccination

6.3 Therapeutic Evaluation of Peptide Vaccine

6.3.1 Prostate Cancer

6.3.2 Breast Cancer

6.3.3 Gastric Cancer

6.3.4 Lung Cancer

6.3.5 Pancreatic Cancer



7. Global Peptide Vaccine Market Overview

7.1 Peptide Vaccine – Does have Long & Secure Future?

7.2 Peptide Patents Insights

7.3 Peptide Vaccine Pipeline Overview



8. Global Peptide Vaccine Market Dynamics

8.1 Accelerative Parameters

8.1.1 Peptidomics

8.1.2 Advances in Vaccine Research

8.1.3 Stronger Clinical Pipeline

8.1.4 Emergence of Biologics in Cancer Therapy

8.2 Commercialization Challenges & Modifications

8.2.1 Funding & Legal Issues

8.2.2 Designing & Manufacturing Challenges

8.2.3 Route of Administration

8.2.4 Peptide Pharmacodynamics & Pharmacokinetics



9. Global Peptide Vaccine Market Future Perspectives



10. Global Peptide Vaccine Clinical Pipeline by Company, Indication & Phase

10.1 Research

10.2 Preclinical

10.3 Phase-I

10.4 Phase-I/II

10.5 Phase-II

10.6 Phase-III



11. Discontinued & Suspended Peptide Vaccine Clinical Pipeline by Company, Indication & Phase

11.1 No Development Reported

11.2 Discontinued

11.3 Market Withdrawal

11.4 Suspended



12. Competitive Landscape

12.1 AFFiRiS

12.2 AlerGenetica

12.3 Anergis

12.4 Antigen Express

12.5 Apitope Technology

12.6 Araclon Biotech

12.7 Artificial Cell Technologies

12.8 Benovus Bio

12.9 Bionor Pharma

12.10 Circassia

12.11 Celgene Corporation

12.12 Galena Biopharma

12.13 Immatics biotechnologies

12.14 Immune Design

12.15 ImmunoCellular Therapeutics

12.16 Invectys

12.17 ISA Pharmaceuticals

12.18 Lytix Biopharma

12.19 Medinet

12.20 Spotlight Innovation (Memcine Pharmaceuticals)

12.21 Merck Serono

12.22 OncoTherapy Science

12.23 Peptech

12.24 Peptinov

12.25 PeptiVir

12.26 Pharmasyntez

12.27 Renaptys Vaccines

12.28 Sumitomo Dainippon Pharma

12.29 TapImmune

12.30 Targovax

12.31 Vaxon Biotech

Figure 1-1: History of Vaccines

Figure 2-1: Peptides - Amino Acid & Proteins

Figure 2-2: Diversification of Vaccines

Figure 2-3: Sub-Unit Vaccines V/S Traditional Vaccines

Figure 3-1: Classification of Peptide Vaccine by Source

Figure 3-2: Classification on Basis of Length

Figure 3-3: On the Basis of Epitopes

Figure 4-1: Synthetic Peptide Manufacturing Process

Figure 4-2: Selection of Synthetic Immunogenic Constructs

Figure 4-3: Solid phase Peptide Synthesis v/s Solution Phase Technique.

Figure 4-4: Fmoc Cleavage

Figure 4-5: Boc Cleavage

Figure 5-1: Mechanism of Immune Activation of CD4+ and CD8+ T-Cells

Figure 5-2: Delivery System Pathways by Adjuvants

Figure 5-3: Liposome & the Modes of Chemically Different Antigen Incorporation.

Figure 6-1: TAAs on the Basis of Tissue Distribution

Figure 6-2: Vaccination via Peptide Loaded Dendritic Cells

Figure 6-3: Mechanism of Action of Sipuleucel-T

Figure 6-4: Use of HER-Vaxx Antigen for Production of Antibodies

Figure 6-5: Peptides Applied in Treating Cancer

Figure 7-1: Global Peptide Drug Market (US$ Billion), 2014-2020

Figure 7-2: Approved Peptide Drugs

Figure 7-3: Global - Peptide Vaccine Clinical Pipeline by Phase (%), 2016

Figure 7-4: Global - Peptide Vaccine Clinical Pipeline by Phase (Numbers), 2016

Figure 7-5: Global - Active & Suspended Peptide Vaccine Clinical Pipeline by Phase (%), 2016

Figure 7-6: Global - Active & Suspended Peptide Vaccine Clinical Pipeline by Phase (Numbers), 2016

Figure 8-1: Global - Peptide Market Favorable Parameters

Figure 8-2: Global - Peptide Vaccine Market Commercialization Challenges

Figure 8-3: Routes of Administration

Figure 12-1: Anergis – Clinical Pipeline

Figure 12-2: Apitope Technology – Clinical Pipeline

Figure 12-3: Benovus Bio – Clinical Pipeline

Figure 12-4: Bionor Pharma – Clinical Pipeline

Figure 12-5: Circassia – Clinical Pipeline

Figure 12-6: Celgene - Clinical Pipeline

Figure 12-7: Galena Biopharma - Clinical Pipeline

Figure 12-8: Immatics Biotechnologies - Clinical Pipeline

Figure 12-9: Immune Design – Clinical Pipeline

Figure 12-10: ImmunoCellular Therapeutics - Clinical Pipeline

Figure 12-11: Invectys – Clinical Pipeline

Figure 12-12: ISA Pharmaceuticals – Clinical Pipeline

Figure 12-13: Lytix Biopharma - Clinical Pipeline

Figure 12-14: Merck Serono – Clinical Pipeline

Figure 12-15: Onco Therapy Science – Clinical Pipeline

Figure 12-16: Peptinov - Clinical Pipeline

Figure 12-17: Sumitomo Dainippon Pharma – Clinical Pipeline

Figure 12-18: Tapimmune – Clinical Pipeline

Figure 12-19: Targovax - Clinical Pipeline

Figure 12-20: Vaxon Biotech - Clinical Pipeline

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
L29 - L34, First Floor
Block L,Connaught Place
New Delhi-110001
+91-11-47067990

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Global Peptide Vaccine Market & Clinical Pipeline Outlook 2020 Report here

News-ID: 1040817 • Views: 250

More Releases from Kuick Resarch

Global Cell Therapy Market To Surpass US$ 35 Billion By 2026
Global cell therapy market is expected to surpass US$ 35 Billion by 2026 as per recent report “Global Cell Therapy Market, Clinical Trials, Therapy Price & Opportunity Insight 2026” published by Kuick Research. Increasing investment, gaining research and development activities along with new technological advancement will drive the global cell therapy market. Download Report: https://www.kuickresearch.com/report-global-cell-therapy-market,-clinical-trials,-therapy-price-and-opportunity-insight-2026.php “Global Cell Therapy Market, Clinical Trials, Therapy Price & Opportunity Insight 2026” Report Highlights: • Global Cell Therapy
Cell Therapy Market Size Growth Cell Therapy Clinical Trials Market Forecast 202 …
Cell therapies are still in the infancy stages of the clinical development and are expected to evolve in the market with a vast number of opportunities in the healthcare industry. In order to form a stable base for process evaluation and development it will be essential to understand the quality of cell based products. With an increasing number of cell therapies and clinical indications being assessed, it is clear that
Global Cell Therapy Market Size Analysis Clinical Trials Growth Forecast 2026
"Global Cell Therapy Market, Clinical Trials, Therapy Price & Opportunity Insight 2026" Report Highlights: • Global Cell Therapy Market Opportunity: More Than US$ 35 Billion by 2026 • Cell Therapy Clinical Trial Insight by Indication, Company & Country • Global Cell Therapy Clinical Pipeline: 767 Cell Therapies • Globally Marketed Cell Therapies: 25 Cell Therapies • Maximum Number of Marketed Cell Therapies In USA: 15 Therapies • Price & Product Insight By Region/Country • Regional Analysis of the Cell Therapy Market Download
CAR T Cell Therapy Changing The Cancer Oncology Drug Market Landscape
" Global CAR T Cell Therapy Market & Clinical Trials Insight 2024" Report Highlights: • CAR T-Cell Therapies Delivery Pipeline & Mechanism of Action • Sales Analysis of CAR - T Cell Therapy • CAR - T Cell Therapy Market Opportunity: US$ 700 Million • CAR-T Cell Therapies Clinical Pipeline by Company, Indication & Phase: 236 Therapies • CAR-T Cell Therapies in Highest Phase: Preclinical • Marketed CAR-T Cell Therapies: 2 ( Yescarta & Kymriah) • Global Market Scenario of

All 5 Releases


More Releases for Peptide

Peptide Therapeutics Market | Forecast up to 2024
Global Peptide Therapeutics Market: Overview This report provides in-depth region wise and country wise analysis of the peptide therapeutics market. Stakeholders of this report include manufacturers of peptide products, raw material suppliers, nutraceutical and cosmeceutical companies, food processing industries and new players planning to enter the market. It further provides qualitative and quantitative analysis of the global peptide therapeutics market. Qualitative analysis comprises market dynamics, trends, product overview, and country-level market
Peptide Vaccine Market Peptide Vaccine Clinical Pipeline Report 2020
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Peptide Vaccine: A Prologue to Sub-Unit Vaccines 1.1 Introduction 1.2 Glimpse of Antiquity 2. Need of Peptide Vaccines 2.1 Why Peptides – More Desirable 2.2 Peptide Vaccines V/S Traditional Vaccines 3. Classification of Peptide Vaccines 3.1 On the Basis of Sources Obtained 3.2 On the Basis of Length 3.3 On the Basis of
Global Natriuretic Peptide Market Research Report 2017
Report Hive Market Research Released a New Research Report of 107 pages on Title " Global Natriuretic Peptide Market Research Report 2017 "with detailed Analysis, Forecast and Strategies. In this report, the global Natriuretic Peptide market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented
Global Peptide Therapeutics Pipeline Insight 2015
Peptides are small molecules of varying molecular masses that consist of amino acids joined with the help of peptide bonds (CONH2). One end of the molecule consists of carboxyl (COOH2) group while the other end has amino (NH2) group giving rise to polarity. Biologically, they are very important and found to play an important role in various anabolic and catabolic processes. They are essential component of cell signaling pathways, immune
Global Peptide Vaccine Market & Pipeline Insight
Peptide vaccines are peptides that exhibit pharmacological properties by activating human immune system rather than showing pharmacologically activity by themselves. They are administered into body to enter in lymph nodes where they induce long lasting immune response. They utilize immune system and develop long term acquired immunity which has capability to prevent future incidences of pathogen attack. Every living cell in human body has surface markers as an instrument to
Animal Antibacterial Peptide 2024 Market Research Report
Peptides are derived from animal source and possess antibacterial activity that comes under animal antibacterial peptides. They contain residue of amino acids generally about 15 to 45. Antibacterial peptides are the effector molecules of innate immunity. Majority of the antibacterial peptides are cationic in nature. In insects, the cecropin type of linear peptide without cysteine are found. Now, more than 900 sequences of proteins and antibacterial peptides from plants and